Robert J. More - 27 May 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: Director
Issuer ticker: VIR
Reported as of: 27 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2026, 19:25:00 UTC
Prior SEC filing: 19 Dec 2025
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Vanina de Verneuil, Attorney-In-Fact

Key filing fact

Robert J. More filed Form 4 for Vir Biotechnology, Inc. (VIR) on 28 May 2026.

Key facts

This page summarizes Robert J. More's Form 4 filing for Vir Biotechnology, Inc. (VIR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 May 2026, 19:25.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001207792 Primary reporting owner

MORE ROBERT J

Relationship: Director
Address: C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Signature date: 28 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Award

Transaction value
Shares: +8,000
Change %: +20%
Price: $0.000000^*
Shares after: 48,656
Date: 27 May 2026
Ownership: Direct
Footnotes: F1, F2

VIR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 509,917
Date: 27 May 2026
Ownership: See footnote
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +16,000
Change %
Price: $0.000000^*
Shares after: 16,000
Date: 27 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $9.10
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

Footnote F2

The RSUs will vest in full on May 27, 2027.

Footnote F3

Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

Footnote F4

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.